Business
Final Results
Final Results.
About this update from 4basebio Plc
[{"type":"text","content":"\n \n 3 June 2021\n \n 4basebio UK Societas\n \n(\"4basebio\", the \"Company\" or the “Group”)\n Final Results\n The Board of 4basebio UK Societas is pleased to report the results for the financial year ended 31 December 2020. \n Highlights\n \n Spin out of DNA operations from 4basebio AG (now 2Invest AG) before year end\n Expansion into 12,000 square foot freehold office, laboratory and warehousing space near Cambridge in Q3 2020\n Development of UK DNA and nanoparticle scaling and validation team Q4 2020\n Admission of newly formed 4basebio UK Societas Group to AIM in February 2021\n Signed research collaboration and evaluation license agreements with Royal Holloway University of London for development of a non-viral vector for treatment of Duchenne muscular dystrophy in April 2021\n \n Overview\n The 4basebio UK Societas group of companies (“the Group”) was spun out of 4basebio AG, a German listed company, on 8 December 2020. The Company seat was subsequently transferred to the UK and the Company was admitted to AIM on 17 February 2021.\n The Group is a specialist life sciences group of companies focused on supplying therapeutic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of these DNA/RNA based products to patients.\n Its focus is the validation, scaling and supply of proprietary high quality GMP (Good Manufacturing Practice) grade synthetic DNA as well as proprietary non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavour to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.\n This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.\n For further enquiries, please contact:\n \n \n \n 4basebio UK Societas \n +44 (0)12 2396 7943\n \n \n Heikki Lanckriet, CEO\n \n \n \n \n +44 (0)20 7213 0880\n \n \n \n Cairn Financial Advisers LLP (Nominated Adviser)\n \n \n \n Jo Turner / Sandy Jamieson\n \n \n \n \n \n \n \n \n finnCap Ltd (Broker)\n \n \n \n \n Geoff Nash/Richard Chambers/Charlotte Sutcliffe\n +44 (0...